Cargando…

Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial

BACKGROUND: Nonsteroidal anti-inflammatory drugs are widely used for migraine, but gastrointestinal tolerability limits use. We previously reported results from the first treatment period of this 2-period, randomized, controlled study comparing DFN-15—an oral, ready-made liquid solution of a selecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipton, Richard B, Munjal, Sagar, Dodick, David W, Tepper, Stewart J, Serrano, Daniel, Iaconangelo, Charlie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920610/ https://www.ncbi.nlm.nih.gov/pubmed/33658842 http://dx.doi.org/10.2147/JPR.S287571

Ejemplares similares

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura
por: Lipton, Richard B, et al.
Publicado: (2021)

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study
por: Munjal, Sagar, et al.
Publicado: (2017)

Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers
por: Pal, Arindam, et al.
Publicado: (2017)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
por: Schwedt, Todd J., et al.
Publicado: (2018)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment
por: Lipton, Richard B., et al.
Publicado: (2019)

Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult‐to‐Treat Migraine Headaches
por: Tepper, Stewart J., et al.
Publicado: (2019)

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study
por: Kawata, Ariane K., et al.
Publicado: (2021)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
por: Landy, Stephen, et al.
Publicado: (2018)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review
por: Ailani, Jessica, et al.
Publicado: (2023)

Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

Treatment preferences and the selection of acute migraine medications: results from a population-based survey
por: Lipton, Richard B., et al.
Publicado: (2004)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials
por: Ashina, Messoud, et al.
Publicado: (2021)

Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post‐Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial
por: Dodick, David W., et al.
Publicado: (2018)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2023)

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial
por: Yarnitsky, David, et al.
Publicado: (2019)

Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine
por: Spierings, Egilius LH, et al.
Publicado: (2017)

OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
por: Dodick, D, et al.
Publicado: (2013)

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study
por: Jensen, Rigmor H., et al.
Publicado: (2023)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

Strategies of care for acute treatment of migraine
por: Tepper, Stewart J., et al.
Publicado: (2002)

Acute treatment patterns in patients with migraine newly initiating a triptan
por: Lipton, Richard B, et al.
Publicado: (2020)

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
por: Goadsby, P, et al.
Publicado: (2014)

A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN
por: Lipton, Richard B., et al.
Publicado: (2021)

EHMTI-0099. Migraineur perception regarding family burden from chronic migraine: results of the CAMEO (chronic migraine epidemiology & outcomes) study
por: Buse, DC, et al.
Publicado: (2014)

Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)
por: Reginster, Jean-Yves, et al.
Publicado: (2017)

Major life events, stress appraisal, and migraine: results of the American Migraine Prevalence and Prevention (AMPP) study
por: Manack, AN, et al.
Publicado: (2013)

Efficacy and safety of single-dose DFN-15 for treatment of acute postsurgical dental pain: a randomized, double-blind, placebo-controlled study
por: Singla, Neil, et al.
Publicado: (2022)

Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Elmets, Craig A., et al.
Publicado: (2010)

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)
por: Starling, Amaal J, et al.
Publicado: (2018)

Systematic review of outcomes and endpoints in acute migraine clinical trials
por: Houts, Carrie R., et al.
Publicado: (2021)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary
por: Lipton, Richard B., et al.
Publicado: (2021)

TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
por: Bigal, Marcelo E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dnoabrthbal3j01s5t1k23mi9u